最新ニュース Alector (NASDAQ:ALEC) 株価情報

Alector

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Alector Inc

Deep-pocketed investors have adopted a bullish approach towards Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRVL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 27 extraordinary options activities for Marvell Tech. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 9 are puts, totaling $960,360, and 18 are calls, amounting to $972,690.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $110.0 for Marvell Tech over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Marvell Tech's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Marvell Tech's whale activity within a strike price range from $55.0 to $110.0 in the last 30 days. 
<h3>Marvell Tech Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732638661_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.75</td>
<td>$6.7</td>
<td>$6.75</td>
<td>$95.00</td>
<td>$333.4K</td>
<td>1.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.5</td>
<td>$95.00</td>
<td>$237.9K</td>
<td>1.4K</td>
<td>502</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$34.0</td>
<td>$33.95</td>
<td>$34.0</td>
<td>$60.00</td>
<td>$136.0K</td>
<td>1.6K</td>
<td>40</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$10.8</td>
<td>$10.55</td>
<td>$10.8</td>
<td>$95.00</td>
<td>$108.0K</td>
<td>1.6K</td>
<td>100</td>
</tr>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.5</td>
<td>$95.00</td>
<td>$84.5K</td>
<td>1.4K</td>
<td>124</td>
</tr>
</tbody>
</table>

<h3>About Marvell Tech</h3>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
Following our analysis of the options activities associated with Marvell Tech, we pivot to a closer look at the company's own performance.
<h3>Where Is Marvell Tech Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,338,248, with MRVL's price up by 0.33%, positioned at $92.55.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Professional Analyst Ratings for Marvell Tech</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $102.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Marvell Tech, maintaining a target price of $110. 
&#x2A; Reflecting concerns, an analyst from Loop Capital lowers its rating to Hold with a new price target of $95.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Marvell Tech with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

MRVL

This Is What Whales Are Betting On Marvell Tech

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Overweight rating and announces Price Target of $39.

News

Price Target

Initiation

Analyst Ratings

KRNT

Cantor Fitzgerald Initiates Coverage On Kornit Digital with Overweight Rating, Announces Price Target of $39

Trading Ideas

QMCO

Quantum Corporation Shares Resume Trade

Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) locations are reportedly calculating employee pay and hours worked by hand after a ransomware attack on a third-party software provider disrupted how the coffee shop's employees view and manage their schedules and how the company<a href="https://www.benzinga.com/news/asset-sales/24/11/42117962/starbucks-eyes-stake-sale-in-china-amid-fierce-competition-and-falling-sales"> tracks labor hours. </a>
The Details: U.K-based supply chain software provider Blue Yonder first reported that a ransomware attack had disrupted its services last Thursday. The company has indicated it is working "around the clock" with CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) to <a href="https://www.benzinga.com/markets/equities/24/11/41800177/crowdstrike-expands-cybersecurity-reach-in-europe-and-launches-ai-red-team-services">recover </a>from the ransomware attack. It has not disclosed specific details regarding the extent of the impact or the ongoing recovery timeline.
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
Starbucks<a href="https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-25-2024/card/exclusive-starbucks-wrestles-with-ransomware-attack-on-software-supplier-cZJuRHR4rUCg8rOc9LJQ?mod=article_inline"> told </a>the Wall Street Journal that it is paying employees for their scheduled shifts while the Blue Yonder outage continues. If employees work more or less than their scheduled shift they could be&nbsp;overpaid or underpaid, depending on the hours actually worked.&nbsp;
Starbucks said it would ensure that baristas will be paid for all hours worked when the software is back online.&nbsp;
"Keeping our partners (employees) whole despite the outage continues to be our priority and we're ensuring they will receive pay for all hours worked," Starbucks said.&nbsp;
What Else: Several grocery chains in the UK have also reported disruptions and chains including Morrisons and Sainsbury have had to resort to manual processes which affects their ability to fulfill customer orders.&nbsp;
Blue Yonder also provides supply chain software services to other large companies in the US including, Walmart, DHL, and Procter &amp; Gamble. Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) is another Blue Yonder client closely monitoring the situation. Ford spokesperson Ian Thibodeau <a href="https://dataconomy.com/2024/11/26/blue-yonder-hack-leaves-starbucks-and-grocers-in-chaos/">confirmed to</a> Dataconomy the company is aware of the incident and actively investigating its potential effects.
Price Action:  According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Starbucks shares are down 1.07% at $100.75 at the time of publication Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Image: Shutterstock

Tech

CRWD

SBUX

Starbucks' Employee Systems Down After Software Provider Suffers Ransomware Attack

B of A Securities analyst Sherif El-Sabbahy maintains Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) with a Buy and lowers the price target from $66 to $63.5.

BLBD

B of A Securities Maintains Buy on Blue Bird, Lowers Price Target to $63.5

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) with a Overweight.

Reiteration

ALEC

Cantor Fitzgerald Reiterates Overweight on Alector

B of A Securities analyst Ken Hoexter maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Buy and raises the price target from $35 to $38.

SNDR

B of A Securities Maintains Buy on Schneider National, Raises Price Target to $38

Quantum Corporation Shares Halted On Circuit Breaker To The Upside, Stock Now Up 11.6%

Cantor Fitzgerald analyst Ross Osborn maintains Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) with a Overweight and lowers the price target from $14 to $11.

NNOX

Cantor Fitzgerald Maintains Overweight on Nano X Imaging, Lowers Price Target to $11

Bitcoin Cash (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bch/usd">BCH</a>), a cryptocurrency stemming from a 2017 Bitcoin fork, traded lower by 2.9% to $483.68 during Tuesday&#8217;s session as Bitcoin's price slipped from its recent highs, dampening bullish sentiment across the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42183963/microstrategy-coinbase-and-other-bitcoin-linked-stocks-tumble-as-btcs-march-to-100000-stalls">crypto market</a>. 
What To Know: Bitcoin, the industry's flagship asset, was trading at $93,000 as of 11:00am EST retreating after nearing the $100,000 milestone. This resistance level has emerged as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42192364/bitcoin-correction-could-go-as-deep-as-88700-but-125000-year-end-target-remains-in-play-says-standard-chartered">critical psychological</a> and technical barrier.
The broader cryptocurrency market reflected this slowdown, with Bitcoin-related equities also tumbling in pre-market trading. Analysts are signaling caution, citing overextended bullish sentiment and waning momentum. A prominent trader predicted that if Bitcoin fails to surpass $100,000, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42183963/microstrategy-coinbase-and-other-bitcoin-linked-stocks-tumble-as-btcs-march-to-100000-stalls">a correction to $85,600 could follow</a>.
Bitcoin Cash, closely tied to Bitcoin's market trends, could face headwinds throughout Tuesday&#8217;s session as the overall market cools, underscoring its susceptibility to Bitcoin's price movements.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/11/42186167/michael-saylors-microstrategy-convertible-notes-to-buy-bitcoin-offer-no-interest-so-why-are-investors-rushing-to-buy-them">Michael Saylor&#8217;s MicroStrategy Convertible Notes To Buy Bitcoin Offer No Interest, So Why Are Investors Rushing To Buy Them?</a>

$BCH

Why Bitcoin Cash Is Falling Tuesday

Berry Global Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) shares are trading lower on Tuesday. On Monday, the company disclosed an agreement to sell its Specialty Tapes business to Nautic Partners, LLC, for around $540 million, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42179476/berry-global-announces-agreement-to-sell-specialty-tapes-business-to-nautic-partners" rel="noreferrer noopener">subject to closing adjustments</a>.
The divestment aligns with its strategy of focusing on higher-growth, consumer-oriented markets. The company plans to use proceeds from the sale to reduce debt.
The sale is expected to close in the first half of 2025, subject to customary closing conditions.
Including the cash received from its recent HHNF spin-off and the Tapes sale, Berry's pro forma net debt as of September 30, 2024, is expected to be approximately $5.9 billion, representing a 3.5x LTM net leverage ratio.
Berry CEO, Kevin Kwilinski, said, &#8220;Over the past year, Berry has undergone a significant transformation, completing the spin-off of our HHNF business, enhancing our product mix and optimizing our portfolio. The sale of Tapes further supports these efforts and the continued focus on our high-growth consumer portfolio.&#8221;
This month, Berry Global agreed to merge&nbsp;with Amcor plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>) in an all-stock transaction, with the deal valuing Berry&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/11/42069248/amcor-and-berry-seal-the-deal-73-59-per-share-merger-to-forge-packaging-powerhouse" rel="noreferrer noopener">stock at $73.59 per share</a>.
The companies anticipate a $650 million benefit from synergies by the end of year three, including $530 million in annual pre-tax cost savings, $60 million in financial savings, and $60 million from growth synergies.
Berry Global&nbsp;noted the sale of the Tapes business further reinforces the strategic rationale for the combination and has no material impact on the financial profile of the combined entity.
Price Action: BERY shares are down 1.47% at $70.50 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/24/11/42147945/deal-dispatch-starbucks-considers-china-sale-private-equity-bankrupts-snack-company-darwin-financial-talks-mining" target="_blank" rel="noreferrer noopener">Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining</a></li>
</ul>

Equities

Mid Cap

Asset Sales

AMCR

BERY

Merger-Bound Berry Global Agrees To Divest Specialty Tapes Unit For ~$540M

Management

Live On CNBC, Abercrombie & Fitch CEO Fran Horowitz  Discusses Q3 Results, Retail Sector, Growth Outlook

RBC Capital analyst Biraj Borkhataria maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Sector Perform and lowers the price target from $120 to $115.

RBC Capital Maintains Sector Perform on Exxon Mobil, Lowers Price Target to $115

<a href="https://www.benzinga.com/topic/dmt">DMT</a>, or dimethyltryptamine, has intrigued researchers and psychedelic enthusiasts for its profound effects on consciousness. Known for inducing otherworldly visions, from &#8220;machine elves&#8221; to mystical figures, some scientists now propose that DMT may play a key role in extraordinary experiences like vivid dreams, near-death encounters and spiritual awakenings. 
<h3 class="wp-block-heading">DMT: A Naturally Occurring Substance In Humans</h3>
DMT is a naturally occurring compound found in plants, animals and humans. First identified in humans in the 1950s, it gained attention in the 1990s through <a href="https://www.benzinga.com/markets/cannabis/20/12/18522764/more-real-than-real-a-psychiatrist-discusses-dmt">Rick Strassman</a>'s research, where he coined the term ‘the spirit molecule' in <a href="https://psychiatryonline.org/doi/10.1176/appi.ajp.159.8.1448">his 2000 book</a>. Strassman proposed that DMT could induce spiritual experiences and might be produced by the <a href="https://en.wikipedia.org/wiki/File:Pineal_gland.png">pineal gland</a>. While found in the pineal gland of rats, in humans, DMT is only detectable in urine, blood and cerebrospinal fluid, making it difficult to study.
Strassman's theory, as Double Blind <a href="https://doubleblindmag.com/our-brains-make-dmt/">reports</a>, proposed that DMT could be responsible for the vivid visions and transcendental experiences often associated with both near-death encounters and extreme psychological states. &#8220;When Strassman called DMT ‘the spirit molecule,' he meant it rather literally: Its function in the brain, he argued, is simply to elicit psychological states that we call spiritual,&#8221; <a href="https://www.vox.com/the-highlight/379914/dmt-psychedelics-drug-neuroscience-consciousness-ayahuasca">wrote</a> journalist Oshan Jarow in Vox.
<h3 class="wp-block-heading">DMT And Near-Death Experiences</h3>
One of the most compelling aspects of DMT research is its potential connection to <a href="https://www.benzinga.com/markets/cannabis/24/08/40528986/psychedelic-trips-resemble-near-death-experiences-new-study-shows-what-does-it-mean">near-death experiences</a>. A 2019 study found that DMT levels spike in rat brains during cardiac arrest, suggesting it may play a role in the vivid, transformative experiences reported during near-death encounters. This has led some researchers to speculate that DMT's release during extreme stress could trigger the mystical visions often experienced in such situations.
Dr. Ede Frecska, a researcher from the University of Debrecen in Hungary, proposed that DMT could be released in response to the brain's need to preserve itself during near-death situations. "Extrapolating from this finding, one might be tempted to hypothesize that this sudden flood of DMT may provoke the mystical encounters on the border between life and death," Frecska wrote in his work with Strassman.
While this hypothesis remains speculative, it is part of a broader effort to understand how DMT could influence human consciousness during moments of extreme distress or transition.
<h3 class="wp-block-heading">DMT And Dream States</h3>
In addition to its connection with near-death experiences, DMT's potential role in dreams has also intrigued researchers. Some believe it could explain the vivid, spiritual quality of dreams. A 2018 <a href="https://cosmosandhistory.org/index.php/journal/article/view/734/1200">study</a> published in The Journal of Natural and Social Philosophy suggests DMT may be released during sleep, making dreams feel more real. Its small molecular structure allows it to cross the blood-brain barrier, altering perception and possibly contributing to closed-eye visions or hallucinations in darkness or sensory deprivation.
<h3 class="wp-block-heading">The Elusive Nature Of DMT Research</h3>
Despite the growing interest in DMT, much about the molecule remains a mystery. While researchers have identified the necessary enzymes for DMT synthesis in the brain, its exact role in human consciousness is still unclear. As neuroscientist Jimo Borjigin from the University of Michigan noted, "We know nothing—seriously!—about the role of endogenous DMT." The challenges of studying DMT, particularly because it is quickly metabolized in the body, have made it difficult to draw definitive conclusions.
While early research raised concerns about a potential link between elevated DMT levels and psychiatric conditions like schizophrenia, studies have since debunked this theory. "If you've got really high levels of psychedelics that your body is making, maybe that's conferring hallucinations and delusions," <a href="https://lettersandsciencemag.ucdavis.edu/feature/exploring-psychedelics-within-us">said</a> Cassandra Hatzipantelis, a postdoctoral fellow at the UC Davis Institute for Psychedelics and Neurotherapeutics. "But they found no correlation between schizophrenia patients and endogenous psychedelic levels, and it was all thrown out."
As research continues, scientists are beginning to uncover the potential roles of DMT in human consciousness. Whether it's playing a part in near-death experiences, enhancing the quality of dreams, or facilitating profound spiritual experiences, DMT's influence on the brain is a subject of growing interest.
Cover image made with AI

Cannabis

Psychedelics

DMT: The Hidden 'Spirit Molecule' Within Your Body

B of A Securities analyst Nikolay Beliov maintains Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Neutral and raises the price target from $75 to $90.

B of A Securities Maintains Neutral on Zoom Video Comms, Raises Price Target to $90

Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is set to release its third-quarter earnings during Tuesday&#8217;s after-hours session following a strong second quarter performance marked by record sales and <a href="https://www.benzinga.com/news/earnings/24/08/40511659/these-analysts-slash-their-forecasts-on-urban-outfitters-following-q2-results">earnings</a> that surpassed expectations. 
What To Know: In the second quarter, the company reported earnings of $1.24 per share, beating the consensus estimate of $1.01 by 22.77%, and achieved record quarterly sales of $1.35 billion, up 6.13% year-over-year.
Growth in the second quarter was driven by a 3.1% increase in total Retail segment net sales, with comparable sales rising 2% as both digital and retail store sales posted low single-digit gains. Free People and Anthropologie were standouts, with comparable sales growth of 7.1% and 6.7%, respectively, offsetting a 9.3% decline in the Urban Outfitters brand.
Read Also: <a href="https://www.benzinga.com/24/11/42188915/kohls-q3-misses-the-mark-weak-sales-and-ceo-shake-up-send-shares-down">Kohl&#8217;s Q3 Misses The Mark: Weak Sales And CEO Shake-Up Send Shares Down</a>
The Nuuly rental business surged, with segment sales up 62.6%, propelled by a 55% increase in active subscribers. Wholesale sales also grew 15.1%, led by Free People's 17.5% increase in department and specialty store partnerships.
For the third quarter, investors may focus on whether Urban Outfitters can sustain its momentum, particularly in the outperforming Free People and Anthropologie brands, and continue scaling Nuuly's success.
Challenges in the Urban Outfitters brand and any potential macroeconomic headwinds affecting consumer spending will also be key considerations. Third quarter results will be pivotal as the company seeks to maintain its upward trajectory and profitability across all segments.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/42188320/best-buy-says-q3-sales-little-softer-than-expected-on-lower-demand-for-appliances-and-gaming-trims-annual-forecast">Best Buy Says Q3 Sales &#8216;Little Softer Than Expected&#8217; On Lower Demand For Appliances And Gaming, Trims Annual Forecast</a>
<h2 class="wp-block-heading">Is URBN A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/URBN">Urban Outfitters</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Urban Outfitters does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 8.66%, you'll need to buy a share of Manhattan Bridge Capital by the Dec. 31, 2024. Once done, you can expect to receive a nominal payout of $0.12 on Jan. 15, 2025.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/URBN">Urban Outfitters</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, URBN has a 52-week high of $48.89 and a 52-week low of $32.02.

URBN

Urban Outfitters Q3 Preview: Can Record Growth Continue After Strong Q2 Earnings?

B of A Securities analyst Sabrina Abrams upgrades Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) from Neutral to Buy and raises the price target from $285 to $315.

Upgrades

B of A Securities Upgrades Applied Industrial Techs to Buy, Raises Price Target to $315

Wells Fargo analyst Ike Boruchow maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Equal-Weight and raises the price target from $32 to $38.

BBWI

Wells Fargo Maintains Equal-Weight on Bath & Body Works, Raises Price Target to $38

Financial giants have made a conspicuous bullish move on Best Buy Co. Our analysis of options history for Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) revealed 11 unusual trades.
Delving into the details, we found 63% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $184,724, and 7 were calls, valued at $343,144.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $90.0 for Best Buy Co over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Best Buy Co options trades today is 158.14 with a total volume of 15,865.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Best Buy Co's big money trades within a strike price range of $75.0 to $90.0 over the last 30 days.
<h3>Best Buy Co Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732637791_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BBY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$85.00</td>
<td>$91.9K</td>
<td align="right">91</td>
<td align="right">3</td>
</tr>
<tr>
<td>BBY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$5.75</td>
<td>$3.55</td>
<td>$4.38</td>
<td>$90.00</td>
<td>$76.6K</td>
<td align="right">585</td>
<td align="right">177</td>
</tr>
<tr>
<td>BBY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$2.49</td>
<td>$1.05</td>
<td>$1.5</td>
<td>$88.00</td>
<td>$60.0K</td>
<td align="right">120</td>
<td align="right">518</td>
</tr>
<tr>
<td>BBY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$19.85</td>
<td>$16.25</td>
<td>$19.8</td>
<td>$75.00</td>
<td>$59.4K</td>
<td align="right">6</td>
<td align="right">30</td>
</tr>
<tr>
<td>BBY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.4</td>
<td>$9.35</td>
<td>$9.4</td>
<td>$87.50</td>
<td>$48.9K</td>
<td align="right">87</td>
<td align="right">672</td>
</tr>
</tbody>
</table>

<h3>About Best Buy Co</h3>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Present Market Standing of Best Buy Co</h3>
<ul>
<li>Currently trading with a volume of 4,544,823, the BBY's price is down by -8.23%, now at $85.37. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>Expert Opinions on Best Buy Co</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $113.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Best Buy Co, targeting a price of $109. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Best Buy Co, maintaining a target price of $117. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Best Buy Co with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Best Buy Co's Options Frenzy: What You Need to Know

Wells Fargo analyst Jonathan Reeder maintains TXNM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) with a Overweight and raises the price target from $49 to $53.

TXNM

Wells Fargo Maintains Overweight on TXNM Energy, Raises Price Target to $53

Alector drops 31% as Alzheimer's candidate fails in phase 2 trial

Biggest stock movers Tuesday: PSTX, SMTC, ALEC, LESL, WWD and more

BTIG analyst Thomas Shrader maintained a Buy rating on Alector (ALEC – Research Report) yesterday and set a price target of $5.00. Thomas Shrader h...

Alector's Strategic Innovations and Potential in Neurological Treatments Justify Buy Rating

H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating on the shares. The comp...

Alector price target lowered to $7 from $35 at H.C. Wainwright

BTIG lowered the firm's price target on Alector (ALEC) to $5 from $16 and keeps a Buy rating on the shares. The TREM2 activation had little effect ...

Alector price target lowered to $5 from $16 at BTIG

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Alector (ALEC – Research Report). The company's shares closed yes...

TD Cowen Remains a Buy on Alector (ALEC)

Morgan Stanley downgraded Alector (ALEC) to Underweight from Equal Weight with a price target of $3, down from $10, after AL002 did not slow Alzhei...

Alector downgraded to Underweight from Equal Weight at Morgan Stanley

Biggest stock movers Tuesday: PSTX, ARWR, KSS, ALEC, AMGN, EMBC, and more

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today. Graig Suvannavejh's ratin...

Buy Rating Maintained for Alector Despite AL002 Setback, Focus on Promising AL001 and Strong Financials

Mizuho says Alector's (ALEC) top-line Phase 2 results for AL002 in Alzheimer's disease "were non-equivocal, with negative signals on all primary or...

Alector shares may settle in $2.50-$3.50 range, says Mizuho

AMGN

ARWR

EMBC

HSAI

LESL

MAXN

PSTX

RHHBF

RHHBY

RHHVF

SMTC

SRPT

Health Care

Press Releases

Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector to Host Mid-Year Earnings Conference Call

Earnings

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Participate in Upcoming Healthcare Conferences

General

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Financing

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

ABBV

HTGC

Absci

Akebia Therapeutics

Aura Biosciences

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Design Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kodiak Sciences

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Neurogene

Prime Medicine

AVITA Medical

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tango Therapeutics

Valneva

Verve Therapeutics

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

Y-mAbs Therapeutics

Zenas BioPharma

HC Wainwright & Co.

Stifel

Deutsche Bank

Mizuho

Goldman Sachs

WIIM

Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.

Comments

Alector

ニュース

最新ニュース Alector (NASDAQ:ALEC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル